Gail Giltner
Family · Grants Pass, ORNPI 1558413856
Payments from drug & device makers
Across 63 payments — averaging $19.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$154
- Otsuka America Pharmaceutical, Inc.$150
- Novo Nordisk$123
- AstraZeneca$95
- Takeda Pharmaceuticals U.S.A., Inc.$88
- Astellas Pharma US Inc$79
- plus $570 from 16 others
What the payments were for
- Food & beverage$1,18294%
- Education$776%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 8 | $154 |
| Otsuka America Pharmaceutical, Inc. | 8 | $150 |
| Novo Nordisk | 6 | $123 |
| AstraZeneca | 6 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $88 |
| Astellas Pharma US Inc | 2 | $79 |
| Lilly USA, LLC | 4 | $71 |
| AbbVie | 3 | $71 |
| GSK | 2 | $56 |
| Xeris Pharmaceuticals, Inc. | 2 | $52 |
| Pfizer | 2 | $44 |
| Exact Sciences | 2 | $39 |
| Bayer | 2 | $39 |
| Alkermes, Inc. | 2 | $29 |
| Aimmune Therapeutics, Inc. | 1 | $28 |
| Amgen | 2 | $27 |
| Tempus AI, Inc | 1 | $24 |
| Averitas Pharma Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Dexcom, Inc. | 1 | $17 |
| Novartis | 1 | $14 |
How this compares
$1,259 in reported general payments places this provider in the 85th percentile of 1,130 family providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 57 | $61,630 |
| JardianceEmpagliflozin | 28 | $47,023 |
| XareltoRivaroxaban | 21 | $27,815 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $23,148 |
| MyrbetriqMirabegron | 11 | $14,478 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $9,754 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 21 | $8,818 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $5,345 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 85 | $4,886 |
| Gabapentin | 110 | $3,550 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 98 | $2,793 |
| Levothyroxine Sodium | 205 | $2,748 |
| Losartan Potassium | 163 | $2,390 |
| SynthroidLevothyroxine Sodium | 23 | $2,256 |
| Atorvastatin Calcium | 155 | $1,881 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $44 | $61,63057 claims |
| Boehringer IngelheimJardiance | $20 | $47,02328 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $56 | $32,90229 claims |
| Johnson & JohnsonXarelto | $154 | $27,81521 claims |
| Astellas Pharma US IncMyrbetriq | $79 | $14,47811 claims |
| AbbVieSynthroid | $71 | $2,25623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,130 family providers in Oregon.
Other family in Grants Pass
- Nicole ParrottaGrants Pass$3K
- Laura JohnsonGrants Pass$3K
- Rachel PangilinanPortland$103K
- Jodeanna SweeneyCentral Point$45K
- Lani DoserPortland$45K
- David ArnopoleMedford$38K
- Heather HermanCorvallis$34K
- Amy BartramOregon City$33K
- Leah GaedekePortland$26K
- Bobbi Lee RothTualatin$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.